Introduction
Human Immunodeficiency Virus type 2 (HIV-2) was first isolated in 1986 [1] [2] [3] . As compared to the global HIV-1 pandemic, the HIV-2 epidemic has remained essentially confined to West Africa with a limited spread to other regions [4] . In West Africa, between 10-20% of HIV infections are HIV-2 or HIV-1/ HIV-2 dual seropositive [5, 6] corresponding to 1-2 million people living with this virus in the region [7] although prevalence has been waning over the last few decades [6] .
Compared with HIV-1 infection, HIV-2 infection is characterized by a much longer asymptomatic stage, lower plasma viral load, slower CD4 cell count decline, lower AIDS-related mortality rate [4, [8] [9] [10] [11] , lower rates of mother-to-child transmission [12, 13, 14] , genital tract shedding [15] and sexual transmission [16, 17] . Nonetheless, a significant proportion of HIV-2 infected individual's progress to AIDS and may benefit from antiretroviral therapy (ART) [18] .
All antiretrovirals to date have been developed to inhibit HIV-1 replication and many of them are not active against HIV-2. HIV-2 is intrinsically resistant to the non-nucleoside reverse transcriptase inhibitors (NNRTIs) and the fusion inhibitor, enfurvirtide [19] [20] [21] . Moreover, only three protease inhibitors (PI) have potent activity against HIV-2: lopinavir, saquinavir and darunavir [21, 22] . The nucleoside/tide reverse transcriptase inhibitors (NRTIs) appear to be equally potent against HIV-2 as for HIV-1, however different resistance pathways and a lower genetic barrier to resistance make their use problematic [23, 24] . The newer antiretroviral classes, the integrase inhibitors (INI) show promising in vitro activity against HIV-2 isolates [25] [26] [27] [28] . Preliminary studies among HIV-2 infected patients showed that the INI class drugs (raltegravir and elvitegravir) is an interesting option among HIV-2 naïve patients as well as those who experience therapeutic failure [29] , but remains to be formally evaluated through clinical trials. Of note, INI are already included in some guidelines for HIV-2 infection [22] .
There is a lack of evidence-based guidelines on the diagnosis, management and ART use for HIV-2 or HIV-1/HIV-2 dual infections [21, 22, 30, 31] especially in resource-limited settings [21] . The main reasons are that first the efficacy of ART in HIV-2 infection has not been evaluated through randomized clinical trials [7, 32] and second observational cohorts generally have had small numbers of patients and shown relatively poor outcome [33] [34] [35] [36] [37] [38] although emerging data suggest LPV/r-based regimens have reasonable efficacy [35] .
Because of these issues, we designed and organized a West African collaborative cohort of HIV-2 infection within the framework of the International epidemiological Database to evaluate AIDS (IeDEA) [39] . We collected data on all HIV-2 and HIV-1/HIV-2 dually seropositive patients both ARV-naïve and ARV-treated and followed-up in clinical centres in the IeDEA-WA network in the West Africa region. Here, we report the characteristics of HIV-2 and HIV-1/HIV-2 dually seropositive adults in West Africa presenting for care and on ART.
Methods

Description of the Cohort
The organization and structure of the Sub-Saharan IeDEA cohorts have been previously described [39] and the HIV-2 cohort collaboration is a newly formed network of HIV-2 and dually HIV-1/HIV-2 seropositive patients in West Africa embedded in the IeDEA-West Africa group. A total of 13 clinics (all are located in urban areas), in five countries (Benin, Burkina-Faso, Cote d'Ivoire, Mali, Senegal) are participating ( Figure 1 and Table 1 ). All of the sites have the capacity to measure CD4 cell counts, hematology and chemistries. Only two countries (Senegal and Cote d'Ivoire) had an equipped laboratory for performing HIV-2 plasma viral load measurements [40] [41] , however they were not routinely performed.
Schedule of Follow-up
ART was provided by the individual national treatment programs according to their individual treatment algorithms. After initiation into care, patients were typically followed every six months, or were seen in between visits for any intercurrent illness. CD4 count were measured every six months. 
Data Collection
Data Management
Clinical and biological questionnaires are collected and centralized at the IeDEA West Africa, Regional office in the Programme PACCI in Abidjan where they are checked for accuracy and completeness and transfer to the INSERM U897 Epidemiology centre in Bordeaux, France, for statistical analysis and cohort description. The database used for the current manuscript included information recorded at enrolment as well as during follow-up up to December 2011.
Statistical Analysis
Continuous variables are described by their median value and interquartile range (IQR); categorical variables are described as percentages. All statistical tests are two-sided, with a type I error of 5%.
Ethical Aspects
The study was designed and performed in accordance with the Declaration of Helsinki and was approved by the National ethics committee ( 
Results
As of December 2011 the cohort has captured baseline and follow-up data from 1,754 (56% female) HIV-2 or dually seropositive patients, of whom 1,014 (57.8%) have initiated ART (Table 1) . Overall, 1,021 HIV-2 infected patients (551 on ART) and 733 dually seropositive for HIV-1 and HIV 2 (463 on ART) have been enrolled (Table 2) .
Among patients whom were ART-naive, the median age was 42.8 years, interquartile range (IQR) (34.9-49.4) for HIV-2 patients and 40.6 years, IQR (34.4-47.2) for dually seropositive patients (p,0.001). At enrolment, 49.1% of HIV-2 patients had CD4 count $500 cells/mm 3 versus 22.2% for dually seropositive patients (p,0.001) ( Table 2) .
At ART initiation, the median age of HIV-2 patients was 45. In all clinical centers, the most commonly used first-line ART regimen was a protease inhibitors (PI) based regimen, which was initiated in 84.0% of HIV-2 patients and 65.9% for dually seropositive patients. The most common PI based regimen prescribed was lopinavir-ritonavir (AluviaH or KaletraH) for 36.4% HIV-2 patients and 26.9% for dually seropositive patients on ART. Despite the fact that NNRTIs are not recommended among HIV-2 patients due to intrinsic resistance, it was initiated in 39 (7.1%) of HIV-2 patients and 123 (26.6%) of dually seropositive patients (Table 2 ). Finally, 3 NRTIs regimens were prescribed for 8.7% of HIV-2 infected patients and for 6.3% of dually seropositive patients. The most prescribed NRTI regimens among HIV-2 infected patients were the followings zidovune+lamivudine (3TC) (63.3%), stavudine (d4T) +3TC (30.5%), tenofovir+(emtricitabine or 3TC) (2.7%) and didanosine+ (abacavir+d4T) (1.1%).
The median CD4 count at the ART initiation is 166 cells/mm Figure 2 ). Of 551 HIV-2 patients on ART, 32 (5.8%) died and 56 (10.2%) were considered lost to follow-up during the median time on ART of 2.4 years, IQR (0.7-4.3). Of 463 dually seropositive patients on ART, 21 (4.6%) died and 46 (9.9%) were considered lost to follow-up during a median follow on ART of 2.6 years (0.9-5.5). Table 3 summarizes the follow-up characteristics of both ARV-naïve and ARV-treated HIV-2 and dually seropositive patients.
Discussion
The IeDEA-WA-HIV-2 cohort is a multi-centre, multi-country collaboration on HIV-2 and dually seropositive patients in West Africa, the only region of the world where the two viruses are endemic (HIV-2) and epidemic (HIV-1). This is one of the largest datasets in the world on HIV-2 and provides the opportunity to study HIV-2 in resource-limited settings (RLS). The only other large HIV-2 database is the ACHIEV 2 E HIV-2 Collaboration in Europe and North America [35] . The IeDEA-WA HIV-2 cohort aims, first, to build and strengthen an operational and clinical research network that describes HIV-2 case management in RLS. Treatment outcomes and their determinants are being investigated by pooling individual patient data, and should thus appropriately inform policies and programmes by examining various models of care, clinical and operational outcomes. The network is reflecting on a similar successful experience of adult treatment centres in lower income countries [39] and aims to rapidly bridge the gap in clinical and programmatic information for people living with HIV-2. Furthermore, this collaboration includes not only patients on ART but also patient ''in care'' but ARV-naive. In addition, we have also implemented an HIV-2 and HIV-1/HIV-2 Drug Resistance Database that will allow us to conduct surveys of genotypic resistance and virological response in the future. Moreover, we are in the process of implementing and standardizing plasma HIV-2 RNA viral load quantification across sites.
It is important to note that several centres identified as possible sites of enrolment and follow-up of HIV-2 patients in the West African region did not participate in this collaboration because they do not perform routinely HIV serologic testing that discriminates HIV-1 from HIV-2, (e.g. Nigeria, which has the largest number of HIV-infected patients in West Africa).
In West Africa, rapid HIV assays are often used for the diagnosis of HIV-1 or HIV-2 or dual HIV-1/HIV-2 infection. This strategy is based on the demonstration of virus-specifics antibodies using enzyme-linked immunosorbent assay basedtechnique [21, 30, 42, 43] . In the West African region, current serological tests for the diagnosis of HIV-2 include: 1) For screening purposes: Determine, ELISA and Murex ICEVIH1.0. HIV-2 may be underreported because antibody cross-reactivity between HIV-1 and HIV-2 is common and frequently results in misdiagnosis of HIV-2 as HIV-1 or dual infection [44, 45] . Therefore screening tests need high sensitivity for HIV-2, while confirmatory testing may require multiple steps in order to reliably distinguish between HIV-1, HIV-2, and HIV-1/HIV-2 dual infection. The consequence of misdiagnosis that results in HIV-2 and dually seropositive patients going on treatment that ignores their HIV-2 as reported here with 7.1% of HIV-2 patients who had initiated NNRTI regimens because the clinician did not know they had HIV-2 at the time of ART initiation. Dual infection can be proven only by the presence of both HIV-1 and HIV-2 DNA or RNA by specific PCR the isolation of both viruses from the same individual [46] . However plasma HIV-2 RNA may be undetectable using current assays, it cannot be used as a diagnostic test. HIV-2 proviral DNA may be low or repeatedly negative in some asymptomatic individuals, making confirmation of diagnosis difficult [47] .
CD4 count is the most readily available means for monitoring disease progression in HIV-2-infected patients. However, CD4 count often will not increase as rapidly as it generally occurs with successful therapy of HIV-1 mono-infection [33, 34, 48] . It has been reported that there is less and slower CD4 count recovery in older patients with HIV-1, limiting the CD4 interpretation of CD4 trajectory in older HIV-2 patients on ART [49] . Thus, there is no validated definition of immunological failure in HIV-2 infection. Consequently, in West Africa, it is difficult to manage HIV-2 patients with ART failure since there are no commercially available viral load and resistance tests for HIV-2 infection [50] [51] [52] , There are indeed very limited 1 st and 2 nd line treatment options for HIV-2 in most RLS in West Africa. The lack of available second-line HIV-2 therapy options should be considered when choosing first-line ART, as the initial regimen choice, narrows later treatment options. Additionally, in HIV-1/HIV-2 dual infection, clinical management needs to focus on controlling both viruses with agents that are active against both HIV-1 and HIV-2 [21] .
Finally our large study of HIV-2 and HIV-1/HIV-2 dual infection in West Africa suggests that routine clinical care is less than optimal and that management and treatment of HIV-2 could be further informed by ongoing studies and randomized clinical trials in this population.
